P1168 ITPA AND SLC29A1 GENOTYPING BEFORE TRIPLE THERAPY PREDICT SEVERITY OF RIBAVIRIN-INDUCED ANEMIA
Laura Milazzo(University of Milan), Felicia Stefania Falvella, M Galli, Chiara Magni, Cristina Gervasoni(University of Padua), E Calvi(Ospedale Papa Giovanni XXIII), Stefania Cheli, E. Clementi, Simona Landonio(ASST Fatebenefratelli Sacco)
Cited by 0
Related Papers
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
|HIV Medicine|2020|166
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|97